将干细胞“疗法”作为研究进行推销：众筹活动中潜在客户的观点。
Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
作者信息
Snyder Jeremy, Turner Leigh
机构信息
Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 1S6, Canada.
Center for Bioethics, University of Minnesota, N-302 Boyn HS, 410 Church Street SE, Minneapolis, MN 55455, USA.
出版信息
Regen Med. 2018 Jun;13(4):375-384. doi: 10.2217/rme-2018-0007.
AIM
To better understand how prospective customers interpret claims of businesses marketing unproven stem cell products that they are engaging in research activities.
MATERIALS & METHODS: The authors examined 408 crowdfunding campaigns for unproven stem cell interventions for references to research activities.
RESULTS
The authors identified three overarching themes: research as a signifier of scientific credibility; the experimental nature of stem cells as a rationale for noncoverage by insurers; and contributing to the advancement of science by engaging in research.
CONCLUSION
The NIH, US FDA and others should be concerned about being co-opted to misrepresent the nature of these businesses' activities. Efforts are also needed to better inform those considering purchasing unproven stem cell interventions about their relationship to legitimate research.
目的
为了更好地理解潜在客户如何解读那些营销未经证实的干细胞产品的企业所宣称的他们正在开展研究活动这一说法。
材料与方法
作者检查了408个针对未经证实的干细胞干预措施的众筹活动，以查找其中提及研究活动的内容。
结果
作者确定了三个总体主题：研究作为科学可信度的标志；干细胞的实验性质作为保险公司不予承保的理由；通过参与研究为科学进步做出贡献。
结论
美国国立卫生研究院、美国食品药品监督管理局及其他机构应关注被这些企业利用来歪曲其活动性质的情况。还需要做出努力，以便更好地让那些考虑购买未经证实的干细胞干预措施的人了解这些措施与合法研究之间的关系。
Zotero 插件